common side effects of reopro
major hemorrhage
pain
chest pain
hemorrhage
hypotension
nausea
comprehensive list of adverse effects
needed effects
abciximab
active ingredient
reopro
unwanted side effects
medical attention
abciximab side effects
medical attention
body
medicine
side effects
health care professional
side effects
following side effects
significant increase in bleeding between patients
abciximab
active ingredient
reopro
aspirin
heparin
placebo among the patients from the epic trial
emergency
coronary artery bypass grafting
cabg
ptca
authors
surgery
treatment with abciximab with acceptable mortality
bleeding complications
data
data from the thrombolysis
angioplasty in myocardial infarction
tami
pilot study
epilog trial
use of weight-adjusted abciximab infusion
low-dose weight-adjusted heparin
early removal of the femoral sheath
arterial access guidelines
incidence of major bleeding in patients
receiving abciximab
heparin
rates
patients
receiving placebo
immediate discontinuation of abciximab
heparin
event of serious bleeding
compression
common sites of bleeding
femoral artery access site
gi
tract
great care
placing
femoral artery introducer
indwelling
venous lines
place
administration of abciximab
recent puncture sites
clinical trials
incidence of intracranial hemorrhage in treated patients
placebo
incidence of major bleeding events from gi
retroperitoneal
other sites
treated patients
incidence of hematologic side effects
bleeding increases
abciximab
given following
given following full dose thrombolytic therapy
canadian study
involving acute myocardial infarction
ami
patients
researchers
fold increase
bleeding risk in patients
received full dose thrombolytics
adjunctive abciximab
low dose heparin
therapy during rescue
urgent ptca
patients
full dose thrombolytics within the first hours
onset of ami symptoms
abciximab
patients as adjunctive therapy during rescue
ptca within hours of ami
ptca within hours of ami
angioplasty
remaining patients
abciximab
control group
authors
risk of intracranial
fatal bleeding events
non-treated groups
risk for minor bleeding
abciximab-treated group
major bleeding events
patients
receiving abciximab within hours of full dose thrombolytic therapy
study
july
march of the total patients
major bleeding episodes
total of patients
required transfusions
intracranial bleeding
patients
authors
major bleeding
patients
abciximab
hours of full-dose thrombolytic therapy
risk factors
bleeding events in patients
glycoprotein
gp
iib/iiia inhibitors
undergoing percutaneous coronary intervention
pci
advanced age
renal dysfunction
female gender
peripheral vascular disease
lower body weight
duration of gp iib/iiia inhibitor infusion
baseline platelet count
lower baseline hemoglobin
diabetes
elevated peak activated clotting time
according
study
crusade trial
involving patients with non-st-segment elevation
acute coronary syndrome
nsteacs
gp iib/iiia inhibitor
women
greater risk of bleeding than men
excessive dosing
results of another study
patients with nsteacs
pci
men
women
greater incidence of major
minor bleeding complications
transfusions of blood products
hematologic complications
life-threatening side effects of abciximab
thrombocytopenia
cells/mcl
abciximab
standard dose heparin
rate
platelet counts
cells/mcl
).
thrombocytopenia
cells/mcl
abciximab
low-dose weight-adjusted heparin
epilog
rate
platelet counts
cells/mcl
pseudothrombocytopenia
benign laboratory condition
bleeding
stroke
transfusion
repeat revascularization
cause of more
third of low platelet counts in patients
undergoing coronary interventions
abciximab
placebo
incidence of pseudothrombocytopenia
trials
using abciximab
major bleeding
intracranial hemorrhage
decrease in hemoglobin
g/dl
patients
receiving abciximab
standard-dose heparin
major bleeding
patients
receiving abciximab
low-dose heparin
epilog
minor bleeding
including
spontaneous gross hematuria
spontaneous hematemesis
observed blood loss with a hemoglobin decrease of greater than g/dl
decrease in hemoglobin
least g/dl without an
identified bleeding site
patients
receiving abciximab
standard-dose heparin
minor bleeding
patients
receiving abciximab
low-dose heparin
epilog
excess spontaneous major organ bleeding
abciximab
treated patients
weighing kg
addition
patients
greater incidence of major bleeding episodes
patients
years
prior history of gi disease
received thrombolytics
administered heparin
ptca within hours of the onset of ami symptoms
ptca procedure
minutes in length
ptca
anemia
leukocytosis
petechiae
patients
hypersensitivity reactions
protein solutions
abciximab
active ingredient
reopro
anaphylaxis
epinephrine
dopamine
theophylline
antihistamine
corticosteroid therapy
date
anaphylaxis
abciximab therapy
abciximab
formation of human anti-chimeric antibodies
haca
allergic reactions
including anaphylaxis
thrombocytopenia
antibodies
potential benefit of readministration of abciximab
manufacturer
human anti-chimeric antibodies
abciximab
days
initiating therapy
peak
weeks
cardiovascular
side effects
hypotension
patients
hemorrhagic complications
bradycardia
patients
chest pain
patients
peripheral edema
patients
following
following cardiovascular side effects
incidences
patients
abciximab
active ingredient
reopro
patients
placebo
ventricular tachycardia
pseudoaneurysm
palpitation
arteriovenous fistula
incomplete av block
nodal arrhythmia
peripheral coldness
complete av block
embolism
limb
thromboembolism
analysis
study
target trial
patients with renal dysfunction
undergoing pci
receiving
gp iib/iiia inhibitor
i.
e.
tirofiban
abciximab
higher risk
developing
developing ischemic complications
day death
myocardial infarction
urgent revascularization
patients with normal creatinine clearance
gastrointestinal side effects
nausea
vomiting
patients
abdominal pain
patients
following gi system
side effects
incidences
patients
abciximab
active ingredient
reopro
patients
placebo
dyspepsia
diarrhea
ileus
gastroesophageal reflux
enlarged abdomen
dry mouth
nervous system
side effects
headache
hyperesthesia
increased sweating
confusion
patients
following
following nervous system
side effects
incidences
patients
abciximab
active ingredient
reopro
patients
placebo
abnormal vision
dizziness
anxiety
abnormal thinking
agitation
hypesthesia
confusion
muscle contractions
coma
hypertonia
diplopia
respiratory side effects
pulmonary hemorrhage
fatalities
cases
patients
acute myocardial infarction
abnormal chest x-ray at baseline
patients
history of copd
following
following respiratory side effects
incidences
patients
abciximab
active ingredient
reopro
patients
placebo
pneumonia
rales
pleural effusions
bronchitis
bronchospasm
pleurisy
pulmonary embolism
rhonchi
musculoskeletal pain
pain
patients
asthenia
been report
myalgias in less
patients
genitourinary side effects
incidences
patients
abciximab
active ingredient
reopro
patients
placebo
urinary retention
dysuria
abnormal renal function
frequent micturition
cystalgia
urinary incontinence
prostatitis
dermatologic side effects
incidences
patients
abciximab
active ingredient
reopro
pruritus
wound
cellulitis
injection site pain
bullous eruption
inflammation
pallor
side effects
greater frequency in patients
placebo
endocrine side effects
diabetes mellitus
hyperkalemia
pain at the puncture site
incision pain
patients
drug toxicity
patients
receiving abciximab
active ingredient
reopro
abciximab
formation of human anti-chimeric antibodies
haca
most patients
igg
ige
immune globulins
anaphylaxis
abciximab
active ingredient
reopro
binding
gp iib/iiia receptors
human anti-chimeric antibodies
abciximab
days
initiating therapy
peak
weeks
readministration of abciximab
healthy volunteers
human anti-chimeric antibody
haca
response
initial dose
pharmacokinetic disposition of abciximab
antiplatelet activity
group
incidence of haca formation
readministration
clinical significance of a positive haca titer
side effects of reopro
fda
healthcare professional for medical advice
bleeding
blurred vision
confusion
dizziness
faintness
lightheadedness
getting
lying
sitting position
sweating
unusual tiredness
weakness
black, tarry stools
bleeding gums
blood in urine
stools
red spots on skin
unusual bleeding
bruising
chest pain
discomfort
chills
cough
eye pain
fever
general feeling of illness
headache
pale skin
rapid weight gain
shortness of breath
irregular heartbeat
sneezing
sore throat
swelling of hands
ankles
feet
lower legs
tightness in chest
tingling of hands
feet
troubled breathing
unusual tiredness
wheezing
back pain
acid
sour stomach
belching
burning
crawling
itching
numbness
prickling
pins
needles
tingling feelings
changes in vision
delusions
dementia 
fear
heartburn
indigestion
stomach discomfort
pain
mood
mental changes
nausea
nervousness
vomiting